Resultats de la cerca - Denis Soulières

Refinar resultats
  1. 1
    The Present and Future of Biomarkers in Prostate Cancer: Proteomics, Genomics, and Immunology Advancements

    The Present and Future of Biomarkers in Prostate Cancer: Proteomics, Genomics, and Immunology Advancements per Pierre-Olivier Gaudreau, John Stagg, Denis Soulières, Fred Saad

    Publicat 2016
    Obtenir text complet Obtenir text complet
    Revisão
    Afegir a favorits
    Guardat en:
  2. 2
    Mutations in NSCLC and their link with lung cancer-associated thrombosis: A case-control study

    Mutations in NSCLC and their link with lung cancer-associated thrombosis: A case-control study per Luis Corrales, Denis Soulières, Xiaoduan Weng, Mustapha Tehfé, Marie Florescu, Normand Blais

    Publicat 2013
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  3. 3
    Sunitinib therapy for metastatic renal cell carcinoma: recommendations for management of side effects

    Sunitinib therapy for metastatic renal cell carcinoma: recommendations for management of side effects per Christian Kollmannsberger, Denis Soulières, Ralph Wong, Alissa Scalera, Rania Gaspo, Georg A. Bjarnason

    Publicat 2012
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  4. 4
    Multicenter Phase II Study of Erlotinib, an Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck

    Multicenter Phase II Study of Erlotinib, an Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Recurrent or Metastatic Squamous Cell Cancer of the He... per Denis Soulières, Neil Senzer, Everett E. Vokes, Manuel Hidalgo, Sanjiv S. Agarwala, Lillian L. Siu

    Publicat 2003
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  5. 5
    Neutrophil count is associated with survival in localized prostate cancer

    Neutrophil count is associated with survival in localized prostate cancer per Houda Bahig, Daniel Taussky, Guila Delouya, Amal Nadiri, Ariane Gagnon-Jacques, Paule Bodson‐Clermont, Denis Soulières

    Publicat 2015
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  6. 6
    Clinical outcomes in non‐small‐cell lung cancer patients with <i>EGFR</i> mutations: pooled analysis

    Clinical outcomes in non‐small‐cell lung cancer patients with <i>EGFR</i> mutations: pooled analysis per Luis Paz‐Ares, Denis Soulières, I. Melezínek, Joachim Moecks, Lorenz Keil, Tony Mok, Rafael Rosell, Barbara Klughammer

    Publicat 2010
    Obtenir text complet
    Revisão
    Afegir a favorits
    Guardat en:
  7. 7
    Severe immune mucositis and esophagitis in metastatic squamous carcinoma of the larynx associated with pembrolizumab

    Severe immune mucositis and esophagitis in metastatic squamous carcinoma of the larynx associated with pembrolizumab per Fanny Zulay Acero Brand, Nicolas Suter, Jean‐Philippe Adam, B Faulques, Antonio Maietta, Denis Soulières, Normand Blais

    Publicat 2018
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  8. 8
    KRAS Mutation Testing in the Treatment of Metastatic Colorectal Cancer with Anti-EGFR Therapies

    KRAS Mutation Testing in the Treatment of Metastatic Colorectal Cancer with Anti-EGFR Therapies per Denis Soulières, Wenda Greer, Anthony M. Magliocco, David G. Huntsman, Sean Young, Ming‐Sound Tsao, Suzanne Kamel‐Reid

    Publicat 2010
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  9. 9
    Evolving landscape of first-line combination therapy in advanced renal cancer: a systematic review

    Evolving landscape of first-line combination therapy in advanced renal cancer: a systematic review per Aly‐Khan A. Lalani, Daniel Y.C. Heng, Naveen S. Basappa, Lori Wood, Nayyer Iqbal, Deanna McLeod, Denis Soulières, Christian Kollmannsberger

    Publicat 2022
    Obtenir text complet Obtenir text complet
    Revisão
    Afegir a favorits
    Guardat en:
  10. 10
    Gastrointestinal Stromal Tumours: Consensus Statement on Diagnosis and Treatment

    Gastrointestinal Stromal Tumours: Consensus Statement on Diagnosis and Treatment per Martin E. Blackstein, Jean‐Yves Blay, Christopher L. Corless, David K. Driman, Robert H. Riddell, Denis Soulières, Carol J. Swallow, Shailendra Verma

    Publicat 2006
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  11. 11
    Randomized, Placebo-Controlled, Double-Blind, Phase II Study of Axitinib Plus Docetaxel Versus Docetaxel Plus Placebo in Patients With Metastatic Breast Cancer

    Randomized, Placebo-Controlled, Double-Blind, Phase II Study of Axitinib Plus Docetaxel Versus Docetaxel Plus Placebo in Patients With Metastatic Breast Cancer per Hope S. Rugo, Alison Stopeck, Anil A. Joy, Stephen Chan, Shailendra Verma, Aña Lluch, Katherine Liau, Sinil Kim, Paul Bycott, Brad Rosbrook, Angel H. Bair, Denis Soulières

    Publicat 2011
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  12. 12
    Molecular Alterations and Buparlisib Efficacy in Patients with Squamous Cell Carcinoma of the Head and Neck: Biomarker Analysis from BERIL-1

    Molecular Alterations and Buparlisib Efficacy in Patients with Squamous Cell Carcinoma of the Head and Neck: Biomarker Analysis from BERIL-1 per Denis Soulières, Lisa Licitra, Ricard Mesı́a, Éva Remenár, Shau-Hsuan Li, А. А. Карпенко, Marie Chol, Ying A. Wang, Nadia Solovieff, Laurence Bourdeau, Dalila Sellami, Sandrine Faivre

    Publicat 2018
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  13. 13
    Comparative analysis of the phase III clinical trials of anti-PD1 monotherapy in head and neck squamous cell carcinoma patients (CheckMate 141 and KEYNOTE 040)

    Comparative analysis of the phase III clinical trials of anti-PD1 monotherapy in head and neck squamous cell carcinoma patients (CheckMate 141 and KEYNOTE 040) per Sara I. Pai, Sandrine Faivre, Lisa Licitra, Jean-Pascal Machiels, Jan B. Vermorken, Paolo Bruzzi, Viktor Gruenwald, R. Giglio, C. René Leemans, Tanguy Y. Seiwert, Denis Soulières

    Publicat 2019
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  14. 14
    Phase I/II Trial of Erlotinib and Cisplatin in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: A Princess Margaret Hospital Phase II Consortium and National Cancer Institute of Canada Clinical Trials Group Study

    Phase I/II Trial of Erlotinib and Cisplatin in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: A Princess Margaret Hospital Phase II Consortium... per Lillian L. Siu, Denis Soulières, Eric X. Chen, Gregory R. Pond, Soo Chin, P. Francis, Luc Harvey, M. Klein, Wenjiang Zhang, Janet Dancey, Elizabeth A. Eisenhauer, Eric Winquist

    Publicat 2007
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  15. 15
    Comparing programmed death ligand 1 scores for predicting pembrolizumab efficacy in head and neck cancer

    Comparing programmed death ligand 1 scores for predicting pembrolizumab efficacy in head and neck cancer per Kenneth Emancipator, Lingkang Huang, Deepti Aurora-Garg, Tricia Bal, Ezra E.W. Cohen, Kevin J. Harrington, Denis Soulières, Christophe Le Tourneau, Lisa Licitra, Barbara Burtness, Ramona F. Swaby

    Publicat 2020
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  16. 16
    Tremelimumab in Combination with Exemestane in Patients with Advanced Breast Cancer and Treatment-Associated Modulation of Inducible Costimulator Expression on Patient T Cells

    Tremelimumab in Combination with Exemestane in Patients with Advanced Breast Cancer and Treatment-Associated Modulation of Inducible Costimulator Expression on Patient T Cells per Robert H. Vonderheide, Patricia LoRusso, Magi Khalil, Elaina M. Gartner, Divis Khaira, Denis Soulières, Prudence Dorazio, Jennifer A. Trosko, Jens Rüter, G Mariani, Tiziana Usari, Susan M. Domchek

    Publicat 2010
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  17. 17
    Phase I study of Aplidine in a daily×5 one-hour infusion every 3 weeks in patients with solid tumors refractory to standard therapy. A National Cancer Institute of Canada Clinical Trials Group study: NCIC CTG IND 115

    Phase I study of Aplidine in a daily×5 one-hour infusion every 3 weeks in patients with solid tumors refractory to standard therapy. A National Cancer Institute of Canada Clinical... per J. Maroun, K. Bélanger, Lesley Seymour, S. Matthews, James Roach, Jeanne Dionne, Denis Soulières, David J. Stewart, Rakesh Goel, Danielle Charpentier, Glenwood Goss, Eva Tomiak, J. Yau, José Jimeno, G. Chiritescu

    Publicat 2006
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  18. 18
    Aetiological heterogeneity of head and neck squamous cell carcinomas: the role of human papillomavirus infections, smoking and alcohol

    Aetiological heterogeneity of head and neck squamous cell carcinomas: the role of human papillomavirus infections, smoking and alcohol per Nada J. Farsi, Marie‐Claude Rousseau, Nicolas F. Schlecht, Geneviève Castonguay, Paul Allison, Phuc Félix Nguyen‐Tan, Denis Soulières, François Coutlée, Michael Hier, Sreenath Madathil, Eduardo L. Franco, Belinda Nicolau

    Publicat 2017
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  19. 19
    Human Papillomavirus and Overall Survival After Progression of Oropharyngeal Squamous Cell Carcinoma

    Human Papillomavirus and Overall Survival After Progression of Oropharyngeal Squamous Cell Carcinoma per Carole Fakhry, Qiang Zhang, Phuc Félix Nguyen‐Tan, David I. Rosenthal, Adel K. El‐Naggar, Adam S. Garden, Denis Soulières, Andy Trotti, Vilija N. Avizonis, John A. Ridge, Jonathan Harris, Quynh‐Thu Le, Maura L. Gillison

    Publicat 2014
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  20. 20
    Phase I/II trial of Durvalumab plus Tremelimumab and stereotactic body radiotherapy for metastatic head and neck carcinoma

    Phase I/II trial of Durvalumab plus Tremelimumab and stereotactic body radiotherapy for metastatic head and neck carcinoma per Houda Bahig, F. Aubin, John Stagg, Olguta Gologan, Olivier Ballivy, Éric Bissada, Felix‐Phuc Nguyen‐Tan, Denis Soulières, Louis Guertin, Édith Filion, Apostolos Christopoulos, Louise Lambert, Mustapha Tehfé, Tareck Ayad, Danielle Charpentier, Rahima Jamal, Philip Wong

    Publicat 2019
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:

Eines de cerca: